The stock of Radius Health Inc (NASDAQ:RDUS) gapped up by $0.62 today and has $86.55 target or 61.00% above today’s $53.76 share price. The 5 months technical chart setup indicates low risk for the $2.34B company. The gap was reported on Oct, 11 by Barchart.com. If the $86.55 price target is reached, the company will be worth $1.43 billion more.
Gaps up are useful for using as a support level and to some extent as a tradeable event. If investors already hold the stock and experience a price gap up, then its usually a good idea to hold the stock for a stronger up move. Back-tests of these patterns indicate that two-thirds of the times the stock performance improves after the gap. The area gaps close 89% of the time, the breakaway gaps, 2%, the continuation gaps 4% and the exhaustion gaps 61%. The stock increased 3.19% or $1.66 during the last trading session, hitting $53.76. About 2.02M shares traded hands or 116.43% up from the average. Radius Health Inc (NASDAQ:RDUS) has risen 62.36% since March 8, 2016 and is uptrending. It has outperformed by 53.04% the S&P500.
Analysts await Radius Health Inc (NASDAQ:RDUS) to report earnings on November, 3. They expect $-1.04 earnings per share, down 52.94% or $0.36 from last year’s $-0.68 per share. After $-1.01 actual earnings per share reported by Radius Health Inc for the previous quarter, Wall Street now forecasts 2.97% negative EPS growth.
Radius Health Inc (NASDAQ:RDUS) Ratings Coverage
Out of 9 analysts covering Radius Health (NASDAQ:RDUS), 7 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 78% are positive. Radius Health has been the topic of 13 analyst reports since August 7, 2015 according to StockzIntelligence Inc. Cowen & Co reinitiated the stock with “Outperform” rating in Friday, May 6 report. JP Morgan initiated Radius Health Inc (NASDAQ:RDUS) on Friday, October 2 with “Overweight” rating. The firm has “Buy” rating given on Thursday, September 24 by Canaccord Genuity. The rating was initiated by Deutsche Bank with “Buy” on Friday, August 14. H.C. Wainwright maintained the stock with “Buy” rating in Wednesday, September 21 report. On Wednesday, March 30 the stock rating was initiated by Goldman Sachs with “Neutral”. As per Wednesday, February 24, the company rating was downgraded by Jefferies. H.C. Wainwright initiated the stock with “Buy” rating in Monday, May 23 report.
According to Zacks Investment Research, “Radius Health Inc. is a science-driven biopharmaceutical company. It is focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company’s lead product candidate, abaloparatide (BA058), is in development, in both injection (Abaloparatide-SC) and transdermal (Abaloparatide-TD) methods of administration, for the prevention of fractures in post-menopausal women at risk of fracture from osteoporosis. Radius Health Inc. is based in Cambridge, Massachusetts.”
Insitutional Activity: The institutional sentiment increased to 1.32 in 2016 Q2. Its up 0.03, from 1.29 in 2016Q1. The ratio improved, as 20 funds sold all Radius Health Inc shares owned while 33 reduced positions. 22 funds bought stakes while 48 increased positions. They now own 42.68 million shares or 5.94% more from 40.29 million shares in 2016Q1.
Blackrock Group Incorporated Limited has 18,488 shares for 0% of their US portfolio. Nationwide Fund Advsrs accumulated 23,270 shares or 0% of the stock. Pictet Asset Mngmt Ltd owns 216,060 shares or 0.03% of their US portfolio. Franklin Resource owns 464,200 shares or 0.01% of their US portfolio. Fifth Third Commercial Bank holds 3,421 shares or 0% of its portfolio. Financial Architects accumulated 0% or 43 shares. Moreover, Td Asset Management Inc has 0% invested in Radius Health Inc (NASDAQ:RDUS) for 14,444 shares. Alps Advsrs Inc accumulated 0.02% or 60,460 shares. Aqr Cap Ltd Limited Liability Company last reported 0% of its portfolio in the stock. The Iowa-based Principal Financial Grp Incorporated Incorporated has invested 0% in Radius Health Inc (NASDAQ:RDUS). Voya Investment Mgmt owns 14,214 shares or 0% of their US portfolio. Alexandria Ltd Liability Com last reported 0% of its portfolio in the stock. Wealthtrust holds 0.01% of its portfolio in Radius Health Inc (NASDAQ:RDUS) for 350 shares. Fmr Limited Liability holds 0.03% or 6.46 million shares in its portfolio. Tourbillon Cap Prns Lp accumulated 1.67% or 2.28 million shares.
More recent Radius Health Inc (NASDAQ:RDUS) news were published by: Fool.com which released: “Why Radius Health Inc. Dropped 45% in January” on February 08, 2016. Also Fool.com published the news titled: “Why Radius Health Inc. is Screaming Higher Today” on February 22, 2016. Philly.com‘s news article titled: “Radius Health eyes drug launch, expands in Wayne” with publication date: June 22, 2016 was also an interesting one.
RDUS Company Profile
Radius Health, Inc. is a biopharmaceutical firm focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis. The Company’s clinical pipeline also includes an investigational abaloparatide transdermal patch for use in osteoporosis and the investigational drug RAD1901 for use in hormone-driven and hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. The Company’s preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for use in cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.